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Summary
Objective: To report the clinical, laboratory and sonographic findings in 76 adult
cases of dengue hemorrhagic fever (DHF).
Patients and methods: A dengue 3 epidemic occurred in Havana City from June 2001
to March 2002. 12,889 cases were reported, with 81 DHF cases. From this, 76
serologically confirmed cases were studied descriptively.
Results: Bronchial asthma and white race were important risk factors for the severe
form of the disease. Fever (100%), headache (92.1%), myalgia (76.3%), arthralgia
(73.7%) and retro-orbital pain (57.7%) were the most frequent general symptoms.
Vomiting and abdominal pain were observed in 59.2% and 48.6% of cases, respectively.
The most common bleeding site was the vagina (64%), followed by the skin (55.2%).
Eighteen patients (23.6%) had shock syndrome. Laboratory findings included throm-
bocytopenia (100%), hemoconcentration (93.4%), an increase in liver enzymes
(82.8%), and leukopenia (71%). Ultrasound detected thickening of the gallbladder
wall in 35.1%, pleural effusion in 20.3%, and splenomegaly in 12.9% of cases.
Conclusion: These findings contribute to a better understanding of the clinical
aspects of DHF in adult patients due to the dengue 3 virus.
# 2005 International Society for Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.* Corresponding author. Tel.: +53 7 2020450/53 7 2020633; fax: +53 7 2046051.
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Dengue fever is at present the most important
arthropod-borne viral disease in terms of morbidity
and mortality. There are four dengue serotypes in
circulation worldwide (DEN 1, 2, 3 and 4). Dengue
virus infection causes a spectrum of illness ranging
from asymptomatic cases to dengue hemorrhagic
fever/dengue shock syndrome (DHF/DSS), which is
endemic throughout most tropical and subtropical
regions of the world.1,2
Cuba suffered an extensive epidemic of classical
dengue in 1977—78 caused by DEN 1. This was
followed by an explosive DEN 2 epidemic in 1981
of more than 300,000 dengue cases, including
10,312 severe ones.3
There was no viral activity between 1982 and
1996 anywhere in the country, but in January
1997, a DEN 2 outbreak was detected in Santiago
de Cuba municipality (eastern Cuban province).
Serological studies confirmed infection in 3012 indi-
viduals including 205 DHF cases and 12 fatalities.4,5
From June 2001 to March 2002 dengue was again
detected in Cuba, mainly in the city of Havana. Viral
isolation and PCR recovered DEN 3 from these
patients. IgM dengue antibodies were positive in
more than 12,000 patients, including 81 DHF
cases.6
Data obtained from laboratory surveillance dur-
ing the epidemic confirmed that the DEN 3 virus was
the only etiological agent of this outbreak. Ninety-
one DEN 3 isolates were obtained at different times
of the epidemic. The epidemic was eliminated in
March 2002 and since then no confirmed dengue case
has been detected
The following is the report of 76 serologically
and/or virologically confirmed DHF cases from this
epidemic, admitted to the ‘‘Pedro Kourı´’’ Institute
of Tropical Medicine (IPK) in the city of Havana.Table 1 Age and sex distribution of DHF/DSSa cases.
Age group Males (No) Females (No) Total (No)
<20 1 0 1
20—24 1 1 2
25—34 30 10 40
35—44 8 10 18
45—54 8 2 10
55—64 3 2 5
65 0 0 0
Total 51 25 76
a DHF = dengue hemorrhagic fever; DSS = dengue shock syn-
drome.Patients and methods
Seventy-six DHF cases hospitalized at IPK during the
period from June 2001 to March 2002 were studied
descriptively.
All patients were diagnosed as having dengue
infection by an IgM-capture ELISA test.7
Cases were classified according to the PAHO/WHO
Guidelines for the Control and Prevention of Dengue
and Dengue Hemorrhagic Fever in the Americas:8 (1)
fever, (2) hemorrhagic manifestations, including
positive tourniquet test, (3) thrombocytopenia
(<100 platelets  109/L) and (4) hemoconcentra-
tion (hematocrit increased by 20% or more), or other
sign of plasma leakage.Grades for DHF severity were used:8 (I) positive
tourniquet test as the only hemorrhagic manifesta-
tion, (II) spontaneous bleeding, (III) circulatory fail-
ure (narrowing of pulse pressure or hypotension),
and (IV) profound shock with undetectable blood
pressure. Grades III and IV were DSS cases.
The patients’ medical records were examined in
order to establish age, sex, race, previous pathol-
ogies, clinical picture and laboratory-sonographic
findings. The information was entered into a data-
base and results analyzed.Results
At IPK, located in the west of Havana, 76 DHF cases
were admitted during the epidemic (93.8% of the
total DHF cases). Of these, 58 (76.4%) were classi-
fied as grade II, 16 (21%) grade III, and two (2.6%)
grade IV. The two grade IV cases were fatal. There
were no patients diagnosed as having DHF grade I.
Age, sex and race
The youngest case was 16 years old and the oldest
was 64. The maximum incidence was seen in the
ages 25 to 34. Male:female ratio was 2.04 (51
cases):1 (25) (Table 1).
The ethnic distribution (color of skin) of the cases
waswhite(62%),mulatto(21%)andblack(17%),which
is similar to the ethnic distribution in Havana,9 how-
ever, DSS affected a higher proportion of whites
(83.3%). Two patients of black race developed DSS,
one with a history of sickle cell anemia (Table 2).
Previous conditions
The most important previous medical conditions
found were bronchial asthma (18.4%) (p = 0.0005),
more than twice its prevalence in Cuba10 and sickle
cell anemia (2.6%). Table 3 shows other pathological
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Table 2 Ethnic distribution of DHF and DSSa cases.
Ethnic group Cases (N%) Havana’s population distribution(%)b
DHF DSS Total
White 32 (55.2) 15 (83.3) 47 (61.8) 63.0
Mulatto 15 (25.9) 1 (5.6) 16 (21.1) 20.4
Black 11 (18.9) 2 (11.1) 13 (17.1) 16.4
Total 58 18 76 —
a DHF = dengue hemorrhagic fever; DSS = dengue shock syndrome.
b 0.2% Asian origin.
Table 3 Previous medical conditions of DHF/DSSa cases.
Previous condition No. of cases (%)
DHF/DSSb pcpc DSS DHF
N = 76 N = 18 N = 58
Bronchial asthma 14 (18.4) 7.7 4 (22.2) 10 (17.4)
High blood pressure 9 (11.8) 15.5 1 (5.6) 8 (13.7)
Peptic ulcer 4 (5.2) NK 1 (5.6) 3 (5.1)
Diabetes mellitus 2 (2.6) 2.3 0 (0) 2 (3.4)
Sickle cell anemia 2 (2.6) 3.08d 2 (11.1) 0 (0)
NK = not known.
a DHF = dengue hemorrhagic fever; DSS = dengue shock syndrome.
b p = 0.000555.
c Proportion of Cuba’s population (%).10
d Rate of sickle cell anemia (homozygote and heterozygote) in Cuba.
Table 4 Symptoms and signs in DHF/DSSa patients.
Clinical
manifestation
% Clinical
manifestation
%
Fever 100 Asthenia 48.6
Bleeding 100 Anorexia 34.2
Headache 92.1 Diarrhea 28.9
Myalgia 76.3 Shock 23.6
Arthralgia 73.7 Itching 17.1
Vomiting 59.2 Cough 11.8
Retro-orbital pain 57.7 Chest pain 10.5
Abdominal pain 48.6 Dyspnea 9.2
Skin rash 48.6 Conjunctival
congestion
9.2
a DHF = dengue hemorrhagic fever; DSS = dengue shock syn-
drome.backgrounds detected. Two patients with dengue
shock syndrome grade IV had histories of sickle cell
anemia,onehomozygoteandtheotherheterozygote,
one of them white. Both died.
Clinical picture
According to thepatients’medical records, sixgroups
of clinical manifestations were identified: general,
digestive, dermatological, respiratory, hemorrhagic,
and shock syndrome. Thrombocytopenia (55.3%)
alone or with hemorrhagic manifestations was the
main complaint that resulted in hospitalization, fol-
lowed by abdominal pain and/or vomiting (30.3%),
fever (10.5%) and low blood pressure (3.9%).
Table 4 shows that fever, headache, myalgia,
arthalgia, retro-orbital pain and asthenia were
the most common general symptoms seen in
100%, 92.1%, 76.3%, 73.7%, 57.7% and 48.6% of
the patients, respectively. Vomiting (59.2%),
abdominal pain (48.6%), anorexia (34.2%) and diar-
rhea (28.9%) characterized the symptomatic invol-
vement of the digestive system. Rash was seen in
48.6% of the patients, mainly maculopapular
erythema and associated with itching in 13 cases
(17.1%). Respiratory findings included cough
(11.8%), chest pain (10.5%) and dyspnea (9.2%).
Eighteen (23.6%) patients developed shock.All 76 patients had one or more hemorrhagic
manifestations. The most common was vaginal
bleeding (64%), followed by purpuric syndrome
(55.2%) and gingivorrhagia (44.7) (Table 5). The
majority of the hemorrhages were mild and were
not associated with shock.
Clinical evolution
The early clinical manifestations (first and
second day of the disease) were fever, general
symptoms (headache, myalgia, arthalgia, asthenia)
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Table 5 Hemorrhagic manifestations, laboratory and sonographic findings in DHF/DSSa patients.
Hemorrhagic manifestations % Laboratory findings % Sonographic findings (N = 54) %
Vaginal bleedingb 64b Thrombocytopenia 100 Gallbladder wall thickening 35.1
Purpuric syndrome 55.2 Hemoconcentration 93.4 Pleural effusion 20.3
Gingivorrhagia 44.7 Liver enzyme increase 82.8 Splenomegaly 12.9
Epistaxis 19.7 Leukopenia 71 Hepatomegaly 1.8
Hematemesis 14.4 Leukocyturia 15.7 Ascites 1.8
Hematuria 9.2 Creatinine increase 15.7
Melena 7.8 Microscopic hematuria 13.1
Enterorrhagia 6.5
Conjunctival hemorrhage 1.3
a DHF = dengue hemorrhagic fever; DSS = dengue shock syndrome.
b Percentage of women.and vomiting. During the third day some patients
began to hemorrhage or developed symptoms invol-
ving the digestive system, mainly persistent vomit-
ing. Themajority of the hemorrhagic manifestations
began on the fourth to seventh day of the disease,
and at this time it was also common to see the
beginning of abdominal pain and rash (Table 6).
Shock also appeared between the fourth and the
seventh day after the onset of the disease. In the 18
patients with DSS, shock was preceded by vomiting
(83.3%), abdominal pain (72.2%), defervescence
(72.2%) and thorax pain (27.7%).
Laboratory findings
Thrombocytopenia and hemoconcentration (hema-
tocrit increase of 20% or more) were found in 100%
and 93.4% of the patients respectively; both were
generally more severe on the fifth or sixth day of the
disease. Five patients had a rise in the hematocrit
level which did not reach the 20% level. In these
patients pleural effusion was considered an expres-
sion of plasma leakage.
Increase in liver enzyme levels (aspartate and
alanine aminotransferase) and leucopenia were
other frequent findings as shown in Table 5.Table 6 Appearance of clinical manifestations after
the onset of the disease.
Clinical manifestations Number of cases
Day
1—2
Day
3
Day
4—7
Day
8—10
Fever 76 0 0 0
Vomiting 20 8 16 1
Vaginal bleeding 0 2 13 1
Petecchiae 0 0 40 2
Gingivorrhagia 0 5 27 2
Hematemesis 1 0 10 0
Abdominal pain 5 5 26 1
Rash 1 7 27 0
Diarrhea 8 6 8 0
Shock 0 0 18 0Sonographic findings
Ultrasound was performed in 54 patients. Gallblad-
der wall thickening, pleural effusion and splenome-
galy were frequently encountered. However, very
few patients with hepatomegaly or ascites were
seen (Table 5). Pleural effusion was found in the
physical examination of only six (7.8%) patients.
Discussion
Dengue type 3 apparently disappeared from the
Americas during 1980—1994, but in 1994 it was
isolated in Nicaragua, and later reported in Panama,
other central American countries, Mexico and in the
Caribbean islands.11,12
Inthis study,theclinicalpictureofDHFduetoDEN3
inCubaisdescribed.Therewere76DHFcasesstudied,
including two deaths (2.6% case fatality rate).
For almost 20 years there was no evidence of
dengue virus circulation in the city of Havana. Since
the 1981 epidemic the only circulation observed
occurred during September—October 2000 when
138 classical dengue cases caused by DEN 3 and 4
viruses were detected.1 Thus, in 2001 the majority
of the people in the city with preexisting dengue
antibodies were 20 years old or more. There was
only one patient under 20 in this report. Preliminary
studies show 97% secondary infection in 51 DHF
cases (Alvarez M et al., unpublished data). These
epidemiological and serological findings, and other
Cuban observations,3,5 support the preexistence of
antibodies to dengue as the most important risk
factor for DHF.13 Finally, no DHF cases in children
were observed. Children were at risk of a primary
infection but all DHF/DSS cases reported in this
study were adults. In southeast Asian countries
DHF is mainly a disease of childhood while in the
tropical Americas all age groups are involved.14 DHF
in adults in epidemic form was observed for the first
time during the Cuban DHF epidemic of 1981.15
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increased, mainly in the Americas.16—18
The sex distribution of the three Cuban DHF
epidemics has been different. The male:female
ratio of DHF cases in 1981 was 1:5.419, the ratio
was 1:1 in 19974 and in this report it was 2.04:1.
As in previous observations made in Cuba, whites
showed a higher risk of developing the severe dis-
ease than blacks. It is interesting to note that DSS
was observed in two black individuals with a history
of sickle cell anemia and bronchial asthma respec-
tively, both chronic diseases that have previously
been associated with the severe disease. Similar
observations were made in the 1997 and 1981 den-
gue 2 epidemics.15,16
It has previously been suggested that chronic
diseases are a possible risk factor for DHF/DSS.20
In this report a relatively high percentage of the
patients were found to have medical histories of
bronchial asthma (18.4%). By contrast, the preva-
lence of this disease among Cuba’s population is
7.7%.10 A similar finding was reported in the 1981
Cuban epidemic.15
Sickle cell anemia might exacerbate the mani-
festation of DHF, and was observed in both fatal
cases. The clinical and pathological pictures were
typical of DHF/DSS. In one case there was a pre-
ponderance of shock by plasma leakage and in the
other, hemorrhage predominated.
Fever and other general complaints were fre-
quent, but only after the third day of the disease
was the clinical diagnosis of DHF/DSS suspected by
the presence of warning signs (vomiting and abdom-
inal pain mainly in this study) or hemorrhagic man-
ifestations. Vomiting was also seen on the first and
second day, and could be considered as an early
warning sign.
Not many reports on DEN 3 infections producing
DHF in adults have been carried out, especially not
in individuals with dengue infections 20 years apart.
As can be observed, the clinical picture in this report
is less severe than that observed in the same popu-
lation infected by the dengue 2 virus (Cuban epi-
demics of 1981 and 1997) where hepatomegaly,
major bleeding, ascites, pleural effusion and mor-
tality were more frequent.4,15
This study has found that the frequent increase of
liver enzymes agrees with other authors’ find-
ings.21,22 However, this increase was not associated
with hepatomegaly or jaundice.
Several authors report hepatomegaly as a com-
mon sign in DHF21—23 while Agarwal et al. found this
sign in only 4%.24 Jaundice is an unusual clinical
manifestation in DHF.25
Gallbladder wall thickening, pleural effusion,
hepatomegaly and ascites were reported as sono-graphic findings with a lower frequency than in
previous studies.25,26 Setiawan reported that
children with DHF in southeast Asia suffered from
pararenal and prerenal collections, pericardial
effusion and pancreatic gland enlargement,27
but this was not found in the present study. The
difference in findings could be attributed to
genetic factors or to the different age of the
patients.
This report is based on the clinical description of
the DHF clinical picture observed during the DEN 3
epidemic which occurred in Cuba from 2001—2002.
The observation of a classical DHF clinical picture
resulting from two dengue infections more than 20
years apart must alert the international scientific
community of the complexity of this phenomenon
and represents a new challenge for the develop-
ment of a safe dengue vaccine.Acknowledgements
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